Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
12 participants
INTERVENTIONAL
2004-01-31
2005-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
nasal application of xylometazoline
xylometazoline
xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
2
nasal application of placebo
xylometazoline
xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
xylometazoline
xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months)
Exclusion Criteria
* Current treatment with nasal decongestants or topical steroids
* Sleep disorders other than obstructive sleep apnea
* Internal medical or psychiatric disorders that interfered with sleep
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital Zurich, Switzerland
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Konrad E Bloch, MD
Role: STUDY_CHAIR
University Hospital, Zürich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pulmonary Division, University Hospital Zurich, Switzerland
Zurich, , Switzerland
Pulmonary Division, University Hospital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Clarenbach CF, Kohler M, Senn O, Thurnheer R, Bloch KE. Does nasal decongestion improve obstructive sleep apnea? J Sleep Res. 2008 Dec;17(4):444-9. doi: 10.1111/j.1365-2869.2008.00667.x. Epub 2008 Aug 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EK-825
Identifier Type: -
Identifier Source: org_study_id